Drug-Drug Interaction Study With Rifampin

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine if the concomitant administration of rifampin with BMS-708163 will affect the Pharmacokinetics of BMS-708163 and to assess safety and tolerability of co-administration BMS-708163 and rifampin

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: PRA Health Sciences
• Treatments: Rifampin

Criteria

Inclusion Criteria:

• Healthy male and postmenopausal female subjects, 18-55 yrs old inclusive

Exclusion Criteria:

• Women of childbearing potential

• Tuberculosis